Ahirwar Dinesh K, Mandhani Anil, Dharaskar Anand, Kesarwani Pravin, Mittal Rama D
Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
BJU Int. 2009 Sep;104(6):867-73. doi: 10.1111/j.1464-410X.2009.08549.x. Epub 2009 Mar 31.
To investigate the association of tumour necrosis factor-alpha gene (TNF-alpha) polymorphisms T-1031C, C-863A, and C-857T with bladder cancer risk and recurrence after bacille Calmette-Guérin (BCG) immunotherapy, as TNF-alpha regulates inflammatory process influencing bladder cancer susceptibility and outcome of BCG immunotherapy.
In all, 220 patients with bladder cancer and 206 controls were recruited. Genotyping was done using allele specific-polymerase chain reaction.
A T-1031C, CC genotype and haplotype -1031C/-863C/-857T showed enhanced susceptibility to bladder cancer, with an odds ratio (OR) of 2.23 and 95% confidence interval (CI) of 1.17-4.26; and an OR of 6.05 and 95%CI of 2.46-14.90, respectively. A T-1031C, CC genotype had a reduced risk of recurrence after BCG treatment (hazard ratio 0.38, 95%CI 0.14-0.98).
The present data suggests that T-1031C (CC) genotype and C/C/T haplotype may confer risk for bladder cancer, moreover T-1031C (CC) decreased the risk of recurrence after BCG immunotherapy.
研究肿瘤坏死因子-α基因（TNF-α）多态性T-1031C、C-863A和C-857T与膀胱癌风险以及卡介苗（BCG）免疫治疗后复发的相关性，因为TNF-α调节炎症过程，影响膀胱癌易感性和BCG免疫治疗的结果。
共招募了220例膀胱癌患者和206例对照。采用等位基因特异性聚合酶链反应进行基因分型。
T-1031C的CC基因型和单倍型-1031C/-863C/-857T显示出对膀胱癌的易感性增强，比值比（OR）为2.23，95%置信区间（CI）为1.17-4.26；以及OR为6.05，95%CI为2.46-14.90。T-1031C的CC基因型在BCG治疗后复发风险降低（风险比0.38，95%CI 0.14-0.98）。
目前的数据表明，T-1031C（CC）基因型和C/C/T单倍型可能赋予膀胱癌风险，此外，T-1031C（CC）降低了BCG免疫治疗后的复发风险。
